New biotechnology for high efficiency purification of live human cells

May 21, 2015

One of the reasons pluripotent stem cells are so popular in medical research is that they can be differentiated into any cell type. However, typical differentiation protocols lead to a heterogeneous population from which the desired type must be purified. Normally, antibodies that react to surface receptors unique to the desired cell are used for this purpose. However, in many cases the purification levels remain poor and the cells can be damaged. New RNA technology produced at CiRA may avoid these problems.

Professor Hirohide Saito at the Dept. of Reprogramming Science is a bioengineer who makes tools for iPSC researchers. His latest technology, the microRNA (miRNA) switch, is designed to detect and sort live cells not by surface receptors, but by miRNAs. miRNA is a better marker of cell types and can therefore improve purity levels. His miRNA switches consist of synthetic mRNA sequences that include a recognition sequence for miRNA and an open reading frame (ORF) that codes a desired gene, such as a regulatory protein that emits fluorescence or promotes cell death. If the miRNA recognition sequence binds to miRNA expressed in the desired cells, the expression of the regulatory protein is suppressed, thus distinguishing the cell type from others that do not contain the miRNA and express the protein.

Senior Lecturer Yoshinori Yoshida is a cardiomyocyte specialist also at the Dept. of Reprogramming Science who immediately saw the potential of this technology. He has been studying how iPS cells can be used to combat cardiac diseases, but has been stymied by unsatisfactory purity levels. Cardiomyocytes are especially difficult to purify because they do not express unique surface receptors. The two scientists therefore collaborated to investigate the effectiveness of miRNA switches for these cells.

By applying the miRNA switches to a defined cardiomyocyte cell line, they were able to identify miRNAs unique to cardiomyocytes. From there, miRNA switches that contained sequences complementary to these miRNAs were constructed. The result was far better purification than that achieved by standard methods. Furthermore, because this technology is RNA-based, it does not integrate into the genome, which makes the cells eligible for clinical application.

Yoshida sees this tool as remarkably simple and something that can be used by stem cell researchers studying any organ. "It is just synthesizing RNA and transfecting them. It is not difficult," he said. To prove this point, he and Saito applied their miRNA switches to the purification of hepatocytes and pancreatic cells, neither of which has unique cell surface markers, finding miRNA switches effective there too.

Intriguingly, the performance of different miRNA switches varied with cell development, suggesting that strategic selection of miRNAs could separate cardiomyocytes at different developmental stages and lead to an even more homogeneous cell pool and potentially better cell therapy outcomes.

Saito believes that with further development, miRNA switches will be applicable to all cell types at all cell stages. "We want to make an active miRNA dictionary for each cell type, so that if we want to isolate this kind of cell type, we know how to use this kind of switch," he said.

"Efficient detection and purification of cell populations using synthetic microRNA switches."

Kenji Miki, Kei Endo, Seiya Takahashi, Shunsuke Funakoshi, Ikue Takei, Shota Katayama, Taro Toyoda, Maki Kotaka, Tadashi Takaki, Masayuki Umeda, Chikako Okubo, Misato Nishikawa, Akiko Oishi, Megumi Narita, Ito Miyashita, Kanako Asano, Karin Hayashi, Kenji Osafune, Shinya Yamanaka, Hirohide Saito and Yoshinori Yoshida

Center for iPS Cell Research and Application - Kyoto University

Related Cardiomyocytes Articles from Brightsurf:

CNIC researchers discover a cell-cleaning system that keeps hearts healthy
The study published in Cell shows that macrophages, a type of immune cell, help cardiac cells to get rid of their waste material, and that this maintains the metabolic and contractile properties of the heart.

Ageing heart cells offer clues to susceptibility of older people to severe COVID-19
Genes that play an important role in allowing SARS-CoV-2 to invade heart cells become more active with age, according to research published today in the Journal of Molecular and Cellular Cardiology.

Direct reprogramming: Defying the contemporary limitations in cardiac regeneration
Repair and regeneration of myocardium are the best possible therapy for the end-stage heart failure patients because the current therapies that can help restore the lost cardiomyocytes are limited to heart transplantation only.

Image analysis technique provides better understanding of heart cell defects
Many patients with heart disease face limited treatment options. Fortunately, stem cell biology has enabled researchers to produce large numbers of cardiomyocytes, which may be used in drug screens and cell-based therapies.

Changing what heart cells eat could help them regenerate
Switching what the powerhouses of heart cells consume for energy could help the heart regenerate when cells die.

Heart attack modeled with human stem cells
A model of ischemic heart disease was developed using human induced pluripotent stem cells (hiPSC).

A kinase identified as possible target to treat heart failure
An unexplored kinase in heart muscle cells may be a good target to treat heart failure, a disease that is only incrementally delayed by existing therapies.

Special cells contribute to regenerate the heart in Zebrafish
It is already known that zebrafish can flexibly regenerate their hearts after injury.

Platform for lab-grown heart cells lets researchers examine functional effects of drugs
The human heart's energy needs and functions are difficult to reproduce in other animals; one new system looks to circumvent these issues and provide a functional view of how different treatments can help ailing cells in the heart following oxygen and nutrient deprivations.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Read More: Cardiomyocytes News and Cardiomyocytes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to